Evidence map›Paper›PMID 30268094›Full record

ArticleBMC gastroenterology2018

Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report.

Wen Xie, Qi Wang, Yuanjiao Gao, Calvin Q Pan

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 18 citations in OpenAlex.

  1. [A case of acetaminophen-induced cholestatic liver injury accompanying severe hypercholesterolemia in children].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  2. Drug-induced vanishing bile duct syndrome: A real world pharmacovigilance study using the FDA adverse event reporting system.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Wen XieCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Qi WangCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yuanjiao GaoCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Calvin Q PanDivision of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Health, New York University School of Medicine, 132-21 41Ave, Flushing, New York, 11355, USA. Panc01@NYU.edu.ORCID http://orcid.org/0000-0002-3723-6688
Capital Medical University · CNNYU Langone Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed drugs and can cause drug-induced liver injury. Although patients with drug-induced liver injury from NSAIDs often recover spontaneously, 3% of them required hospitalization and those with persistent cholestasis present a diagnostic challenge. Recently, a few cases of children with persistent jaundice reported have been linked to the vanishing bile duct syndrome. However, data on adult patients is limited. CASE PRESENTATION: We report herein a case of an adult patient who had persistent cholestasis with hyperlipidemia from the VBDS after ibuprofen use. We described a female patient with severe jaundice after taking ibuprofen, although she had no history of liver disease before. The drug-induced liver injury from ibuprofen was identified by clinical features and liver biopsy, which included the Roussel Uclaf Causality Assessment Method scores of 6 and pathological features of cholestasis with stage four drug-induced injury as well as loss of bile duct structures. The clinical course was featuring with persistently high levels of bilirubin associated with hyperlipidemia over the period of one month, although the laboratory abnormalities were slightly improved spontaneously after the cessation of ibuprofen. Her autoantibodies markers including AMA-M2 ASMA, RO-52, LKM, SLA, and anti-glycoprotein-210 were negative. The second liver biopsy was performed on day 213 due to persistent hyperbilirubinemia. Pathological findings were consistent with the diagnosis of vanishing bile duct syndrome.

conclusionsA rare case of ibuprofen-associated vanishing bile duct syndrome in an adult female patient is presented. Clinicians need to be aware of vanishing bile duct syndrome as a serious consequence of ibuprofen use in adult patients, although ibuprofen is considered to be among the safest NSAIDs.

Indexed as

AdultAnti-Inflammatory Agents, Non-SteroidalChemical and Drug Induced Liver InjuryCholestasisDiagnosis, DifferentialDrug HypersensitivityFemaleHumansHyperbilirubinemiaHyperlipidemiasIbuprofenSyndromeAnti-Inflammatory Agents, Non-SteroidalIbuprofenDrug-induced liver injuryHyperlipidemiaIbuprofenJaundiceVanishing bile duct syndrome

Identifiers

PMID30268094
PMCPMC6162916
OpenAlexW2893649661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.